

Terumo Revises its Full-Year Financial Guidance for FY2021

TOKYO, JAPAN – August 4, 2021 – Terumo Corporation (TSE: 4543) today announced that it revised the full-year financial guidance for the year ending March 2022 (FY2021) which was first announced on May 12, 2021.

1. Full-year financial guidance for FY2021 (From April 1, 2021 to March 31, 2022)

	Revenue (Million yen)	Adjusted operating profit (Million yen)	Operating profit (Million yen)	Profit for the year attributable to the owners of the parent (Million yen)	Earnings per share (Yen)
Prior guidance	670,000 to 680,000	124,000 to 130,000	107,000 to 113,000	82,000 to 86,500	108.46 to 114.42
Revised guidance	685,000	137,000	120,000	92,000	121.69
Change in amount	5,000 to 15,000	7,000 to 13,000	7,000 to 13,000	5,500 to 10,000	
Rate of change	0.7% to 2.2%	5.4% to 10.5%	6.2% to 12.1%	6.4% to 12.2%	
(Reference) Results for FY2020	613,842	115,927	98,386	77,268	102.33

2. Reasons for the revision

In the first quarter of FY2021, the healthcare market experienced a recovery in demand as there was increase in medical exams, diagnostics, hospitalizations, and elective procedures which has been postponed across various clinical departments due to COVID-19. Consequently, Terumo displayed strong financial results, with growth exceeding expectation in all 3 companies (Cardiac and Vascular Company, General Hospital Company, Blood and Cell Technologies Company). This contributed to both revenue and adjusted operating profit reaching highest-ever quarter record. The revision to the full-year financial guidance (Revenue, Adjusted operating profit, Operating profit, and Profit for the year attributable to the owners of the parent) takes in account of this success of the first quarter.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Disclaimer

Among the information that Terumo discloses, the forward-looking statements including financial projections contain potential risks and uncertainty since these are made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results might differ from those statements due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.